ALLMedicine™ Hutchinson-Gilford Progeria Syndrome Center
Research & Reviews 191 results
https://doi.org/10.1161/CIRCULATIONAHA.122.060002
Circulation Gordon LB, Norris W et. al.
Mar 16th, 2023 - Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare, fatal, premature aging disease caused by a toxic protein called progerin. Circulating progerin has not been previously detected, precluding research using readily available biological sa...
https://clinicaltrials.gov/ct2/show/NCT00916747
Feb 27th, 2023 - Hutchinson-Gilford Progeria Syndrome (Progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise. The mutation for this disease has been identified and re...
https://clinicaltrials.gov/ct2/show/NCT02579044
Feb 27th, 2023 - This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utili...
https://doi.org/10.1080/01942638.2022.2158054
Physical & Occupational Therapy in Pediatrics; Malloy J, Berry E et. al.
Jan 12th, 2023 - Limited information is available on impairments, activity limitations and participation restrictions in youth with Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic premature aging disease. The purposes were to: (1) describe range of mot...
https://doi.org/10.1016/j.gim.2022.11.003
Genetics in Medicine : Official Journal of the American C... Suzuki M, Jeng LJB et. al.
Dec 13th, 2022 - The U.S. Food and Drug Administration recently approved lonafarnib as the first treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies. This approval was primarily based on a comparison of patien...
Drugs 1 results see all →
Clinicaltrials.gov 7 results
https://clinicaltrials.gov/ct2/show/NCT00916747
Feb 27th, 2023 - Hutchinson-Gilford Progeria Syndrome (Progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise. The mutation for this disease has been identified and re...
https://clinicaltrials.gov/ct2/show/NCT02579044
Feb 27th, 2023 - This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utili...
https://clinicaltrials.gov/ct2/show/NCT05229991
Feb 8th, 2022 - Background: Hepatitis D virus (HDV) was identified as the infectious agent causing viral hepatitis in the presence of hepatitis B virus (HBV). While HDV can replicate autonomously inside the hepatocyte, the virus requires co-infection with HBV to ...
https://clinicaltrials.gov/ct2/show/NCT04512963
Sep 22nd, 2021 - PRG Science & Technology Co., Ltd. (PRG S&T) is developing Progerinin (SLC-D011) for the treatment of the rare aging diseases Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS). Progerin, an abnormal splice variant of the inner n...
https://clinicaltrials.gov/ct2/show/NCT03895528
Apr 15th, 2021 - This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no app...
News 9 results
https://reference.medscape.com/viewarticle/945192
Feb 24th, 2021 - Pediatric Endocrinology Zokinvy (lonafarnib) Lonafarnib, an oral farnesyltransferase inhibitor, is indicated to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS). It was also approved for processing-deficient progeroid la...
https://reference.medscape.com/viewarticle/945183
Feb 24th, 2021 - Zokinvy (lonafarnib) Lonafarnib, an oral farnesyltransferase inhibitor, is indicated to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS). It was also approved for processing-deficient progeroid laminopathies with heteroz...
https://www.onclive.com/view/ftase-inhibition-holds-promise-for-ras-targeting-and-beyond
Dec 5th, 2020 - Alan L. Ho, MD, PhD For more than 20 years, researchers have known that the RAS pathway is involved in a wide variety of cancer types. RAS proteins normally switch between an active state, which is bound by guanosine triphosphate, and an inactive...
https://www.medpagetoday.com/cardiology/chf/71312
Feb 22nd, 2018 - The early cardiovascular death typical of Hutchinson-Gilford progeria syndrome may hide a surprising level of asymptomatic left ventricular (LV) diastolic dysfunction, researchers found. In a single-center series of 27 consecutive patients, ages 2...
http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies
For Immediate Release: November 20, 2020 Today, the U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-defici...